Advertisement
U.S. markets open in 7 hours 31 minutes
Advertisement

Gain Therapeutics, Inc. (GANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.7200+0.2300 (+9.24%)
At close: 04:00PM EST
2.9800 +0.26 (+9.56%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close2.4900
Open2.5400
Bid0.0000 x 1200
Ask0.0000 x 800
Day's Range2.5400 - 2.9500
52 Week Range2.0000 - 6.1900
Volume195,398
Avg. Volume60,319
Market Cap43.159M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-1.8100
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GANX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gain Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 03/08/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • GlobeNewswire

    Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

    BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research taking place Tuesday, December 5, 2023. Fireside Chat

  • GlobeNewswire

    Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

    Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis Results published in PLOS ONE in collaboration with Institute for Research in Biomedicine BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identi

  • GlobeNewswire

    Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

    BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will participate on a panel during the AI Driven Drug Discovery Summit taking place at the Sheraton Boston Hotel, in Boston, Massachusetts December 5-6, 2023. AI Driven Drug Discovery SummitDate: Wednesday, D